Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
One of the more thought-provoking endocrine therapy studies so far: PREcoopERA.
This preoperative window study randomized premenopausal HR+/HER2- breast cancer patients to:
- Giredestrant plus triptorelin
- Anastrozole plus triptorelin
- Giredestrant alone
…with Ki67 reduction before surgery as the primary biologic endpoint.
What makes the design especially interesting is that the study tested two separate hypotheses simultaneously:
- Could next-generation ER degradation + OFS outperform standard AI + OFS?
- Could deep ER blockade alone potentially replace OFS in younger patients?
Results showed marked Ki67 reductions across all arms:
- Giredestrant plus triptorelin: -79.6%
- Anastrozole plus triptorelin: -73.7%
- Giredestrant alone: -68.2%
No significant difference was observed between the two OFS-containing arms, while giredestrant monotherapy — despite clear biologic activity — did not meet non-inferiority versus giredestrant + triptorelin.
Early data, but so far another signal that OFS is here to stay in premenopausal women… even in the era of next-generation ER degraders.”
More posts featuring Matthew Kurian.